Nevirapina Mylan (Nevirapine)

Nevirapine, the active ingredient in Nevirapina Mylan, is a non‑nucleoside reverse transcriptase inhibitor presented as an oral dosage form for oral use. It treats HIV‑1 infection in combination with other antiretroviral agents, helping to suppress viral replication in adults and children. GNH USA supplies Nevirapina Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is a non‑nucleoside reverse transcriptase inhibitor used in the management of HIV‑1 infection. - HIV‑1 infection: used with other antiretroviral agents to achieve viral suppression. - Prevention of mother‑to‑child transmission: reduces the risk of HIV transmission when administered to pregnant women. - Treatment‑experienced patients: provides an option for individuals with resistance to other antiretroviral classes.

Nevirapine may cause a range of adverse reactions, from mild to severe. Awareness of these effects helps clinicians monitor patients appropriately.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal upset. - Fatigue: general feeling of tiredness. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Abdominal pain: mild stomach discomfort.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate discontinuation. - Hepatic failure: signs of liver injury such as jaundice. - Severe rash: extensive or bullous skin lesions. - Hypersensitivity reactions: including fever and eosinophilia. - Neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes indicating liver damage.

Nevirapine requires careful monitoring and patient education to minimize risks. - Monitor liver function: obtain baseline and periodic liver enzyme tests. - Assess for rash: discontinue therapy promptly if severe skin reactions develop. - Check for drug interactions: especially with CYP450 inducers or inhibitors. - Use caution in pregnancy: safety data are limited; evaluate risk‑benefit. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nevirapine interacts with several medicines, necessitating vigilance.

Major Interactions (Avoid): - Rifampicin: markedly reduces nevirapine plasma levels. - St. John’s wort: induces metabolism, lowering efficacy. - Protease inhibitors (e.g., ritonavir): increase nevirapine concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Efavirenz: may increase neuropsychiatric side effects. - Zidovudine: additive bone‑marrow suppression potential. - Hormonal contraceptives: nevirapine may reduce contraceptive effectiveness.